Skip to main content
SpringerLink
Log in

Modulation of AraC by Fludarabine: Results of Salvage Therapy by AMLCG

  • Conference paper
Acute Leukemias VIII

Part of the book series: Haematology and Blood Transfusion / Hämatologie und Bluttransfusion ((HAEMATOLOGY,volume 40))

  • 105 Accesses

Abstract

Fludarabine was shown to increase the intracellular formation of AraCTP during treatment with AraC both in vitro and in vivo and had significant activity in patients with advanced acute myeloid leukemia (AML) when used in combination with AraC in phase II studies. However, the efficacy of fludarabin as chemo-modulatior of the AraC metabolism has not yet been assessed in phase III studies. Based on the S-HAI salvage regimen comprizing high-dose AraC q 12 hours on days 1,2,8, and 9 and idarubicin on days 3,4,10, and 11, the German AML Cooperative Group initiated a prospective randomized comparison between fludarabine q 12 hours on days 1, 2, 8, and 9 in addition to S-HAI as compared with S-HAI alone. Of 91 patients having entered the ongoing study 66 are fully evaluable at the present time (median age 54 years, range 20-75). Twenty-five patients had refractory disease or early relapses, 39 patients had relapses after a preceding CR of more than six months duration and one patient had a second relapse. Thirty patients achieved a remission (CR, 45%; PR, 3%) while the non-response rate was 32% and 20% suffered from early death. The application of fludarabine resulted in a longer duration of neutropenia (38 versus 32 days). Severe non-hematologic toxicity (WHO III/IV°) consisted mainly of nausea/vomiting (26% versus 13%), diarrhea (23% versus 10%), mucositis (14% versus 19%), and bleeding (11% versus 0%) and infectious complications included pneumonia (57% versus 39%), FUO (60% versus 45%), and bacteremia (49% versus 16%). The sequential test has not yet decided for either superiority of fludarabine or equality of both study arms.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Amadori S, Meloni G, Petti MC, Papa G, Miniem R, Mandelli F. (1989) Phase II trial of intermediate dose ARA-C (IDAC) with sequential mitoxantrone (MITOX) in acute myelogenous leukemia. Leukemia 3: 112–114.

    PubMed  CAS  Google Scholar 

  2. Anaissie EJ, Kontoyiannis DP, O’Brien S, Kantarjian H, Robertson L, Lerner S, Keating MJ. (1998) Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 129: 559–566.

    PubMed  CAS  Google Scholar 

  3. Archimbaud E, Fenaux P, Reiffers J, Cordonnier C, Leblond V, Travade P, Troussard X, Tilly H, Auzanneau G, Marie JP, et al. (1993) Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukemia. Leukemia 7: 372–377.

    PubMed  CAS  Google Scholar 

  4. Archimbaud E, Leblond V, Michallet M, Cordonnier C, Fenaux P, Travade P, Dreyfus F, Jaubert J, Devaux Y, Fiere D. (1991) Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia. Blood 77: 1894–1900.

    PubMed  CAS  Google Scholar 

  5. Archimbaud E, Thomas X, Leblond V, Michallet M, Fenaux P, Cordonnier C, Dreyfus F, Troussard X, Jaubert J, Travade P, et al. (1995) Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial [see comments]. J Clin Oncol 13:11–18.

    PubMed  CAS  Google Scholar 

  6. Arlin Z, Case DC, Jr., Moore J, Wiernik P, Feldman E, Saletan S, Desai P, Sia L, Cartwright K. (1990) Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute non-lymphocytic leukemia (ANLL). Lederle Cooperative Group. Leukemia 4:177–183.

    PubMed  CAS  Google Scholar 

  7. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1985) Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 103: 620–625.

    PubMed  CAS  Google Scholar 

  8. Berman E, Wiernik P, Vogler R, Velez Garcia E, Bartolucci A, Whaley FS. (1997) Long-term follow-up of three randomized trials comparing idarubicin and daunorubicin as induction therapies for patients with untreated acute myeloid leukemia. Cancer 80: 2181–2185.

    Article  PubMed  CAS  Google Scholar 

  9. Bishop JF, Lowenthal RM, Joshua D, Matthews JP, Todd D, Cobcroft R, Whiteside MG, Kronenberg H, Ma D, Dodds A, et al. (1990) Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group. Blood 75: 27–32.

    PubMed  CAS  Google Scholar 

  10. Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D, Bradstock K, Enno A, Wolf MM, Fox R, et al. (1996) A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 87:1710–1717.

    PubMed  CAS  Google Scholar 

  11. Bjorkholm M, Liliemark J, Gahrton G, Grimfors G, Gruber A, Hast R, Juliusson G, Jarnmark M, Killander A, Kimby E, et al. (1995) Mitoxantrone, etoposide and ara-C vs doxorubicin-DNA, ara-C, thioguanine, vincristine and prednisolone in the treatment of patients with acute myelocytic leukaemia. A randomized comparison. Eur J Haematol 55:19–23.

    Article  PubMed  CAS  Google Scholar 

  12. Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, Patil SR, Davey FR, Berg DT, Schiffer CA, Arthur DC, Mayer RJ. (1998) Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58:4173–4179.

    PubMed  CAS  Google Scholar 

  13. Bow EJ, Loewen R, Cheang MS, Schacter B. (1995) Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen. Clin Infect Dis 21: 361–369.

    Article  PubMed  CAS  Google Scholar 

  14. Buchner T, Hiddemann W, Wormann B, Loffler H, Maschmeyer G, Hossfeld D, Ludwig WD, Nowrousian M, Aul C, Schaefer UW, Sauerland C, Heinecke A. (1992) Longterm effects of prolonged maintenance and of very early intensification chemotherapy in AML: data from AMLCG. Leukemia 6 Suppl 2:68–71.

    Google Scholar 

  15. Buchner T, Urbanitz D, Hiddemann W, Ruhl H, Ludwig WD, Fischer J, Aul HC, Vaupel HA, Kuse R, Zeile G, Nowrousian MR, Konig HJ, Walter M, Wendt FC, Sodomann H, Hossfeld DK, von Paleske A, Loffler H, Gassmann W, Hellriegel KP, Fulle HH, Lunscken C, Emmerich B, Pralle H, Pees HW, Pfreundschuh M, Bartels H, Koeppen KM, Schwerdtfeger R, Donhuijsen-Ant R, Mainzer K, Bonfert B, Koppler H, Zurborn KH, Ranft K, Thiel E, Heinecke A. (1985) Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol 3:1583–1589.

    PubMed  CAS  Google Scholar 

  16. Cassileth PA, Andersen JW, Bennett JM, Harrington DP, Hines JD, Lazarus HM, Mazza JJ, McGlave PP, O’Connell MJ, Paietta E, et al. (1992) Escalating the intensity of post-remission therapy improves the outcome in acute myeloid leukemia: the ECOG experience. The Eastern Cooperative Oncology Group. Leukemia 6Suppl 2: 116–119.

    PubMed  Google Scholar 

  17. Clavio M, Carrara P, Miglino M, Pierri I, Canepa L, Balleari E, Gatti AM, Cerri R, Celesti L, Vallebella E, Sessarego M, Patrone F, Ghio R, Damasio E, Gobbi M. (1996) High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia. Haematologica 81: 513–520.

    PubMed  CAS  Google Scholar 

  18. Cohen J, Donnelly J, Worsley A, Catovsky D, Goldman J, Galton D. (1983) Septicaemia caused by viridans streptococci in neutropenic patients with leukaemia. Lancet 2: 1452–4

    Article  PubMed  CAS  Google Scholar 

  19. Estey E. (1996) Treatment of refractory AML. Leukemia 10: 932–936.

    PubMed  CAS  Google Scholar 

  20. Estey E, Plunkett W, Gandhi V, Rios MB, Kantarjian H, Keating MJ. (1993) Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma 9: 343–350.

    Article  PubMed  CAS  Google Scholar 

  21. Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O’Brien S, Escudier S, Robertson LE, Koller C, Kornblau S, et al. (1994) Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 12: 671–678.

    PubMed  CAS  Google Scholar 

  22. Gandhi V, Estey E, Keating MJ, Plunkett W (1993) Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 11:116–124.

    PubMed  CAS  Google Scholar 

  23. Gandhi V, Estey E, Keating MJ, Plunkett W. (1993) Biochemical modulation of arabinosylcytosine for therapy of leukemias. Leuk Lymphoma 10 Suppl: 109–114.

    Article  PubMed  Google Scholar 

  24. Harousseau J, Reiffers J, Hurteloup P, et al. (1989) Treatment of relapsed acute myeloid leukemia with idarubicin and intermediate-dose cytarabine. Journal of Clinical Oncology 7:45–9

    PubMed  CAS  Google Scholar 

  25. Herzig R, Hines J, Herzig G, Wolff S, Cassileth P, Lazarus H, Adelstein D, Brown R, Coccia P, Strandjord S, Mazza J, Fay J, Phillips G. (1987) Cerebellar toxicity with high-dose cytosine arabinoside. Journal of Clinical Oncology 5: 927–32

    PubMed  CAS  Google Scholar 

  26. Hiddemann W. (1991) Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens. Ann Hematol 62: 119–128.

    Article  PubMed  CAS  Google Scholar 

  27. Hiddemann W, Kreutzmann H, Straif K, Ludwig WD, Mertelsmann R, Donhuijsen Ant R, Lengfelder E, Arlin Z, Buchner T. (1987) High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia. Blood 69: 744–749.

    PubMed  CAS  Google Scholar 

  28. Hiddemann W, Martin WR, Sauerland CM, Heinecke A, Buchner T. (1990) Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy. Leukemia 4:184–188.

    PubMed  CAS  Google Scholar 

  29. Huhmann IM, Watzke HH, Geissler K, Gisslinger H, Jager U, Knobl P, Pabinger I, Korninger L, Mannhalter C, Mitterbauer G, Schwarzinger I, Kalhs P, Haas OA, Lechner K. (1996) FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia. Ann Hematol 73:265–271.

    Article  PubMed  CAS  Google Scholar 

  30. Jolson H, Bosco L, Bufton M, Gerstman B, Rinsler S, Williams E, Flynn B, Simmons W, Stadel B, Faich G, Peck C. (1992) Clustering of adverse drug effects: Analysis of risk factors for cerebellar toxicity with high-dose cytarabine. Journal of the National Cancer Institute 84: 500–5

    Article  PubMed  CAS  Google Scholar 

  31. Kern W, Aul C, Maschmeyer G, Kuse R, Kerkhoff A, Grote-Metke A, Eimermacher H, Kubica U, Wormann B, Büchner T, Hiddemann W, for the German AML Cooperative Group. (1998) Granulocyte colony-stimulating factor shortens critical neutropenia and prolongs disease free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukemia. Ann Hematol 77:115–122.

    Article  PubMed  CAS  Google Scholar 

  32. Kern W, Aul C, Maschmeyer G, Schönrock-Nabulsi R, Ludwig WD, Bartholomaus A, Bettelheim P, Wormann B, Buchner T, Hiddemann W, for the German AML Cooperative Group. (1998) Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with highrisk acute myeloid leukemia: results of a age-adjusted prospective randomized comparison. Leukemia 12:1049–1055.

    Article  PubMed  CAS  Google Scholar 

  33. Kern W, Behre G, Rudolf T, Kerkhoff A, GroteMetke A, Eimermacher H, Kubica U, Wormann B, Buchner T, Hiddemann W, for the German AML Cooperative Group. (1998) Failure of fluconazole prophylaxis to reduce mortality and the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. Cancer 83: 291–301.

    Article  PubMed  CAS  Google Scholar 

  34. Kern W, Matylis A, Gruneisen T, Huber C, GroteMetke A, Wormann B, Buchner T, Ohnesorge J, Ludwig WD, Hiddemann W, for the German AML Cooperative Group. (1999) Modulation of arac by fludarabine: results of salvage therapy by AMLCG. Ann Hematol 78: S5

    Google Scholar 

  35. Kern W, Schleyer E, Unterhalt M, Wormann B, Buchner T, Hiddemann W. (1997) High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study. Cancer 79: 59–68.

    Article  PubMed  CAS  Google Scholar 

  36. Lazarus HM, Vogler WR, Burns CP, Winton EF. (1989) High-dose cytosine arabinoside and daunorubicin as primary therapy in elderly patients with acute myelogenous leukemia. A phase I-II study of the Southeastern Cancer Study Group. Cancer 63: 1055–1059.

    Article  PubMed  CAS  Google Scholar 

  37. Lowenberg B, Suciu S, Archimbaud E, Haak H, Stryckmans P, de Cataldo R, Dekker AW, Berneman ZN, Thyss A, van der Lelie J, Sonneveld P, Visani G, Fillet G, Hayat M, Hagemeijer A, Solbu G, Zittoun R. (1998) Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy— the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol 16: 872–881.

    PubMed  CAS  Google Scholar 

  38. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, Mclntyre OR, Frei E. (1994) Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 331: 896–903.

    Article  PubMed  CAS  Google Scholar 

  39. Mitus AJ, Miller KB, Schenkein DP, Ryan HF, Parsons SK, Wheeler C, Antin JH. (1995) Improved survival for patients with acute myelogenous leukemia [see comments]. J Clin Oncol 13:560–569.

    PubMed  CAS  Google Scholar 

  40. Montillo M, Mirto S, Petti MC, Latagliata R, Magrin S, Pinto A, Zagonel V, Mele G, Tedeschi A, Ferrara F. (1998) Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. Am J Hematol 58:105–109.

    Article  PubMed  CAS  Google Scholar 

  41. Nokes TJ, Johnson S, Harvey D, Goldstone AH. (1997) FLAG is a useful regimen for poor prognosis adult myeloid leukaemias and myelodysplastic syndromes. Leuk Lymphoma 27:93–101.

    PubMed  CAS  Google Scholar 

  42. Parker JE, Pagliuca A, Mijovic A, Cullis JO, Czepulkowski B, Rassam SM, Samaratunga IR, Grace R, Gover PA, Mufti GJ. (1997) Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 99: 939–944.

    Article  PubMed  CAS  Google Scholar 

  43. Patt YZ, Peters RE, Chuang VP, Wallace S, Mavligit G. (1983) Effective retreatment of patients with colorectal cancer and liver metastases. Am J Med 75: 237–240.

    Article  PubMed  CAS  Google Scholar 

  44. Pavlovsky S, Gonzalez Llaven J, Garcia Martinez MA, Sobrevilla P, Eppinger Helft M, Marin A, Lopez Hernandez M, Fernandez I, Rubio ME, Ibarra S, et al. (1994) A randomized study of mitoxantrone plus cytarabine versus daunomycin plus cytarabine in the treatment of previously untreated adult patients with acute nonlymphocytic leukemia. Ann Hematol 69:11–15.

    Article  PubMed  CAS  Google Scholar 

  45. Reiffers J, Huguet F, Stoppa AM, Molina L, Marit G, Attal M, Gastaut JA, Michallet M, Lepeu G, Broustet A, Pris J, Maraninchi D, Hollard D, Faberes C, Mercier M, Hurteloup P, Danel P, Tellier Z, Berthaud P. (1996) A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75. Leukemia 10: 389–395.

    PubMed  CAS  Google Scholar 

  46. Russo D, Candoni A, Grattoni R, Bertone A, Zaja F. (1998) Fludarabine and cytosine-arabinoside for poor-risk acute myeloid leukemia [letter]. Haematologica 83: 281–282.

    PubMed  CAS  Google Scholar 

  47. Schiller G, Gajewski J, Territo M, Nimer S, Lee M, Belin T, Champlin R. (1992) Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. Blood 80: 2977–2982.

    PubMed  CAS  Google Scholar 

  48. Spadea A, Petti MC, Fazi P, Vegna ML, Arcese W, Awisati G, Aloe Spiriti MA, Latagliata R, Meloni G, Testi AM, et al. (1993) Mitoxantrone, etoposide and intermediate-dose Ara-C (MEC): an effective regimen for poor risk acute myeloid leukemia. Leukemia 7: 549–552.

    PubMed  CAS  Google Scholar 

  49. Visani G, Tosi P, Zinzani PL, Manfroi S, Ottaviani E, Testoni N, Clavio M, Cenacchi A, Gamberi B, Carrara P, et al. (1994) FLAG (fludarabine + highdose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of ‘poor risk’ acute myeloid leukemias. Leukemia 8:1842–1846.

    PubMed  CAS  Google Scholar 

  50. Vogler WR, Velez Garcia E, Weiner RS, Flaum MA, Bartolucci AA, Omura GA, Gerber MC, Banks PL. (1992) A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. J Clin Oncol 10:1103–1111.

    PubMed  CAS  Google Scholar 

  51. Whitehead J. AnonymousNew York: Ellis Horwood, (1992) The design and analysis of sequential clinical trials (second edition).

    Google Scholar 

  52. Wiernik PH, Banks PL, Case DC, Jr., Arlin ZA, Periman PO, Todd MB, Ritch PS, Enck RE, Weitberg AB. (1992) Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 79: 313–319.

    PubMed  CAS  Google Scholar 

  53. World Health Oraganization. Anonymous A handbook for reporting results of cancer treatment. Geneva: WHO publications, (1979)

    Google Scholar 

  54. Yates J, Glidewell O, Wiernik P, Cooper MR, Steinberg D, Dosik H, Levy R, Hoagland C, Henry P, Gottlieb A, Cornell C, Berenberg J, Hutchison JL, Raich P, Nissen N, Ellison RR, Frelick R, James GW, Falkson G, Silver RT, Haurani F, Green M, Henderson E, Leone L, Holland JF. (1982) Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 60: 454–462.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University Hospital Großhadern, Department of Medicine III, Ludwig-Maximilians-University, München, Germany

    W. Kern, J. Ohnesorge & W. Hiddemann

  2. Robert-Rössle-Klinik, Charité, Humboldt-University, Berlin, Germany

    A. Matylis & W. D. Ludwig

  3. Krankenhaus Neukölln, Berlin, Germany

    T. Grüneisen

  4. Department of Medicine III, Johannes-Gutenberg-University, Mainz, Germany

    C. Huber

  5. Evangelisches Krankenhaus, Hamm, Germany

    A. Grote-Metke

  6. Department of Hematology and Oncology, Georg-August-University, Göttingen, Germany

    B. Wörmann

  7. Department of Hematology and Oncology, Westfälische-Wilhelms-University, Münster, Germany

    T. Büchner

Authors
  1. W. Kern
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Matylis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Grüneisen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Huber
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Grote-Metke
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. B. Wörmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T. Büchner
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J. Ohnesorge
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. W. D. Ludwig
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. W. Hiddemann
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Internal Medicine A, Germany

    T. Büchner

  2. Department of Internal Medicine III, University Hospital Großhadern Ludwig-Maximilians-University, Marchioninistr. 15, 81377, München, Germany

    W. Hiddemann

  3. Dept. of Internal Medicine, University of Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Germany

    B. Wörmann

  4. Department of Pediatrics, University of Münster, Albert-Schweitzer-Straße 33, 48149, Münster, Germany

    G. Schellong , J. Ritter  & U. Creutzig ,  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Kern, W. et al. (2001). Modulation of AraC by Fludarabine: Results of Salvage Therapy by AMLCG. In: Büchner, T., Hiddemann, W., Wörmann, B., Schellong, G., Ritter, J., Creutzig, U. (eds) Acute Leukemias VIII. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 40. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18156-6_35

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-18156-6_35

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-62109-3

  • Online ISBN: 978-3-642-18156-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation